Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Up After Analyst Upgrade

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price gapped up before the market opened on Tuesday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. The stock had previously closed at $10.10, but opened at $10.40. Bayer Aktiengesellschaft shares last traded at $10.4810, with a volume of 130,543 shares traded.

A number of other equities analysts have also recently commented on BAYRY. Zacks Research cut shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Wall Street Zen raised Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The business’s fifty day simple moving average is $8.25 and its 200-day simple moving average is $8.01. The firm has a market cap of $41.32 billion, a P/E ratio of -116.82, a price-to-earnings-growth ratio of 4.90 and a beta of 0.69. The company has a current ratio of 1.13, a quick ratio of 0.73 and a debt-to-equity ratio of 1.04.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.